The original success of Sildenafil undeniably transformed the pharmaceutical landscape, but placing funds in companies primarily reliant on generic versions presents a challenging picture. Despite early returns were substantial, the expiration of patents and the rise of cheaper alternatives have diminished sales. Consequently, a thorough assessment